APA (7th ed.) Citation

KS, A., C, Y., EF, P., DM, W., JE, L., AJ, C., . . . LJ, E. (2024). Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(4), 729. https://doi.org/10.1158/1078-0432.CCR-22-2256

Chicago Style (17th ed.) Citation

KS, Albain, et al. "Neoadjuvant Trebananib Plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 30, no. 4 (2024): 729. https://doi.org/10.1158/1078-0432.CCR-22-2256.

MLA (9th ed.) Citation

KS, Albain, et al. "Neoadjuvant Trebananib Plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 30, no. 4, 2024, p. 729, https://doi.org/10.1158/1078-0432.CCR-22-2256.